Search Results

You are looking at 41 - 50 of 524 items for :

  • "Adjuvant therapy" x
  • Refine by Access: All x
Clear All
Full access

Comparison of Treatment Strategies for Patients With Clinical Stage T1–3/N2 Lung Cancer

Ya-Fu Cheng, Wei-Heng Hung, Heng-Chung Chen, Ching-Yuan Cheng, Ching-Hsiung Lin, Sheng-Hao Lin, and Bing-Yen Wang

offer surgical treatment and more likely to use induction therapy before resection, whereas European surgeons preferred to offer OP followed by adjuvant therapy in select cases of N2 disease. Different therapeutic methods were compared in previous

Full access

Updates to the Management of Kidney Cancer

Eric Jonasch

Center, and Vice Chair of the NCCN Guidelines Panel for Kidney Cancer, as he introduced his presentation at the NCCN 23rd Annual Conference. Adjuvant Therapy Five adjuvant therapy trials have been conducted in renal cell carcinoma (RCC). The ASSURE

Full access

Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas

Louis Burt Nabors

different: for RTOG 9402, neoadjuvant therapy consisted of PCV chemotherapy before RT, and in EORTC 26951 adjuvant therapy consisted of PCV chemotherapy after RT. However, toxicity from the PCV regimen was an issue in both studies. “A lot of patients did not

Full access

Advances in the Management of Pancreatic Adenocarcinoma

Presented by: Eileen M. O’Reilly

pembrolizumab to maintenance olaparib, with arms stratified by mutation profile and exceptional response to platinum therapy. Adjuvant Therapy: Overall Survival Advantage Proven Based on the phase III PRODIGE 24/CCTG PA.6 trial, the state-of-the-art adjuvant

Full access

New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma

Christopher A. Barker and April K. Salama

also noted that immunotherapies that are robust in the advanced disease setting are now proving their worth as adjuvant treatment. Several effective options are now approved for adjuvant therapy besides observation. Nivolumab is now preferred over

Full access

Radiotherapy in the Multidisciplinary Management of Merkel Cell Carcinoma

Michael D. Green and James A. Hayman

the primary site . JAMA Dermatol 2016 ; 152 : 1001 – 1007 . 21. Fields RC Busam KJ Chou JF . Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma . Cancer 2012 ; 118

Full access

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

E. Gabriela Chiorean, Marco Del Chiaro, Margaret A. Tempero, Mokenge P. Malafa, Al B. Benson III, Dana B. Cardin, Jared A. Christensen, Vincent Chung, Brian Czito, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Christos Fountzilas, Evan S. Glazer, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Ashiq Masood, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Lorenzo Nardo, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Mark J. Truty, Charles Vollmer Jr, Robert A. Wolff, Brian M. Wolpin, Beth McCullough RN, Senem Lubin, and Susan D. Darlow

(albeit used more rarely compared with pancreatic cancer), adjuvant therapy, and first-line or subsequent-line therapy for locally advanced, metastatic, and recurrent disease. Data for systemic therapy in ampullary cancer are very limited; the only phase

Full access

Impact of the First Generation of Children’s Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

Jeffrey S. Dome, Elizabeth A. Mullen, David B. Dix, Eric J. Gratias, Peter F. Ehrlich, Najat C. Daw, James I. Geller, Murali Chintagumpala, Geetika Khanna, John A. Kalapurakal, Lindsay A. Renfro, Elizabeth J. Perlman, Paul E. Grundy, and Conrad V. Fernandez

patients with very low risk WT, as described in the text, who were candidates to receive no adjuvant therapy. The structure of the AREN ‘0’ studies is depicted in Figure 2 . An expanded menu of biologic and clinical prognostic factors, including

Full access

Molecular Profiling of Endometrial Cancer From TCGA to Clinical Practice

Amy Jamieson and Jessica N. McAlpine

, and administer the best adjuvant therapies to improve their outcomes remains the greatest challenge in this disease site. Historical risk stratification systems are based on histomorphologic features, such as grade and histotype, both of which have

Full access

Melanoma, Version 2.2013

Featured Updates to the NCCN Guidelines

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Dominick DiMaio, Martin D. Fleming, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Maria Ho

– 14 Thus, in these high-risk patients, it would seem reasonable to offer SLNB to help define prognostically homogeneous groups for participation in clinical trials of adjuvant therapy. NCCN Guidelines Insights : Metastatic Colon Cancer, Version